• 中文
    • 登錄
    • 聯系我們
    ×
    目錄產品 » 抗體產品 » 一抗 » 抗獨特型(Anti-idiotype)抗體 » Anti-Durvalumab Antibody (7B6), mAb, Mouse

    Anti-Durvalumab Antibody (7B6), mAb, Mouse

    該產品已下架。
    The product is specific for Durvalumab. The antibody is recommended as a capture antibody in a pharmacokinetic (PK) bridging assay with detection antibody GenScript, A02030, Anti-Durvalumab Antibody (4B5), mAb, Mouse.
    A02029
    聯系我們
    Specificity The product is specific for Durvalumab. The antibody is recommended as a capture antibody in a pharmacokinetic (PK) bridging assay with detection antibody GenScript, A02030, Anti-Durvalumab Antibody (4B5), mAb, Mouse.
    Host Species Mouse
    Immunogen Durvalumab
    Conjugate Unconjugated

    Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
    Application Recommended Usage
    ELISA 0.01-0.1 μg/ml

    Form Lyophilized
    Storage Buffer Lyophilized with PBS, pH 7.4, containing 0.02% sodium azide.
    Reconstitution Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.
    Storage Instructions The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles.
    Purification Protein A affinity column
    Isotype Mouse IgG1,κ
    Clonality Monoclonal
    Clone ID 7B6
    Note GenScript can customize this product per customer's request including product size, buffer components, etc.

    Target Background Durvalumab with trade name Imfinzi, is an FDA-approved anti-cancer drug. It is known as a checkpoint inhibitor drug, developed by Medimmune/AstraZeneca. Durvalumab is a human IgG1κ monoclonal antibody. It blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).Anti-Durvalumab Antibody (7B6), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Durvalumab.
    Synonyms Mouse monoclonal antibody to Imfinzi

    For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.


    国产小受呻吟cv视频在线观看